This amendment includes Oramed receiving 3,250,000 shares of Scilex common stock and introduces a covenant to prevent compensation increases for Scilex's senior management while the note is outstanding. Oramed has also deferred a mandatory $6.25 million payment from Scilex to January 31, 2025, securing 5 million shares of Scilex common stock as collateral. Furthermore, Oramed confirmed the receipt of approximately $13.2 million from Scilex, applied towards a $15 million principal payment installment due in December 2024. These developments reflect Oramed's strategic financial management and ongoing collaboration with Scilex.